BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan MSA, Parekh HS, Pandey P, Siskind DJ, Falconer JR. Nose-to-brain delivery of antipsychotics using nanotechnology: a review. Expert Opin Drug Deliv 2020;17:839-53. [PMID: 32343186 DOI: 10.1080/17425247.2020.1762563] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Applied Materials Today 2022;29:101631. [DOI: 10.1016/j.apmt.2022.101631] [Reference Citation Analysis]
2 Jin Z, Han Y, Zhang D, Li Z, Jing Y, Hu B, Sun S. Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients. Pharmaceutics 2022;14:2070. [DOI: 10.3390/pharmaceutics14102070] [Reference Citation Analysis]
3 Awad R, Avital A, Sosnik A. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.07.003] [Reference Citation Analysis]
4 Lofts A, Abu-Hijleh F, Rigg N, Mishra RK, Hoare T. Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs. CNS Drugs 2022. [PMID: 35759210 DOI: 10.1007/s40263-022-00930-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Abdollahzadeh Jamalabadi MY, Xi J. Olfactory Drug Aerosol Delivery with Acoustic Radiation. Biomedicines 2022;10:1347. [DOI: 10.3390/biomedicines10061347] [Reference Citation Analysis]
6 Hinge NS, Kathuria H, Pandey MM. Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's. Applied Materials Today 2022;26:101303. [DOI: 10.1016/j.apmt.2021.101303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Sharma N, Bietar K, Stochaj U. Targeting nanoparticles to malignant tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022. [DOI: 10.1016/j.bbcan.2022.188703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Goel H, Kalra V, Verma SK, Dubey SK, Tiwary AK. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. J Control Release 2021;341:782-811. [PMID: 34906605 DOI: 10.1016/j.jconrel.2021.12.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 Lee D, Minko T. Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics 2021;13:2049. [PMID: 34959331 DOI: 10.3390/pharmaceutics13122049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
10 Bergonzi MC, Bilia AR, Landucci E. Applications of innovative technologies to the delivery of antipsychotics. Drug Discov Today 2021:S1359-6446(21)00426-8. [PMID: 34601123 DOI: 10.1016/j.drudis.2021.09.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Remington G, Hahn MK, Agarwal SM, Chintoh A, Agid O. Schizophrenia: Antipsychotics and drug development. Behav Brain Res 2021;414:113507. [PMID: 34352293 DOI: 10.1016/j.bbr.2021.113507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Emad NA, Ahmed B, Alhalmi A, Alzobaidi N, Al-kubati SS. Recent progress in nanocarriers for direct nose to brain drug delivery. Journal of Drug Delivery Science and Technology 2021;64:102642. [DOI: 10.1016/j.jddst.2021.102642] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
13 Deruyver L, Rigaut C, Lambert P, Haut B, Goole J. The importance of pre-formulation studies and of 3D-printed nasal casts in the success of a pharmaceutical product intended for nose-to-brain delivery. Adv Drug Deliv Rev 2021;175:113826. [PMID: 34119575 DOI: 10.1016/j.addr.2021.113826] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Costa CP, Cunha S, Moreira JN, Silva R, Gil-Martins E, Silva V, Azevedo L, Peixoto AF, Sousa Lobo JM, Silva AC. Quality by design (QbD) optimization of diazepam-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery: Toxicological effect of surface charge on human neuronal cells. Int J Pharm 2021;607:120933. [PMID: 34324988 DOI: 10.1016/j.ijpharm.2021.120933] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
15 Costa CP, Barreiro S, Moreira JN, Silva R, Almeida H, Sousa Lobo JM, Silva AC. In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN). Pharmaceuticals (Basel) 2021;14:711. [PMID: 34451808 DOI: 10.3390/ph14080711] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
16 Seillier A. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neurosci Lett 2021;759:136064. [PMID: 34146641 DOI: 10.1016/j.neulet.2021.136064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Janjua TI, Rewatkar P, Ahmed-Cox A, Saeed I, Mansfeld FM, Kulshreshtha R, Kumeria T, Ziegler DS, Kavallaris M, Mazzieri R, Popat A. Frontiers in the treatment of glioblastoma: Past, present and emerging. Adv Drug Deliv Rev 2021;171:108-38. [PMID: 33486006 DOI: 10.1016/j.addr.2021.01.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 47.0] [Reference Citation Analysis]
18 Froelich A, Osmałek T, Jadach B, Puri V, Michniak-Kohn B. Microemulsion-Based Media in Nose-to-Brain Drug Delivery. Pharmaceutics 2021;13:201. [PMID: 33540856 DOI: 10.3390/pharmaceutics13020201] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
19 Keller LA, Merkel O, Popp A. Intranasal drug delivery: opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2021. [PMID: 33491126 DOI: 10.1007/s13346-020-00891-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 74] [Article Influence: 57.0] [Reference Citation Analysis]
20 Majcher MJ, Babar A, Lofts A, Leung A, Li X, Abu-Hijleh F, Smeets NMB, Mishra RK, Hoare T. In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. J Control Release 2021;330:738-52. [PMID: 33383097 DOI: 10.1016/j.jconrel.2020.12.050] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
21 de Oliveira Junior ER, Santos LCR, Salomão MA, Nascimento TL, de Almeida Ribeiro Oliveira G, Lião LM, Lima EM. Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating. Drug Deliv Transl Res 2020;10:1688-99. [PMID: 32613550 DOI: 10.1007/s13346-020-00816-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]